The 21st joint meeting held by kConFab, ISK, ABCFS, ACCFS and the Family Cancer Clinics of Australia will be held from the 31st of August to the 3rd of September 2021.  Organisation is underway. This year for the first time we will hold a hybrid event; this is a combination of an in-person and online meeting.

Although the named consortia are funded in very different ways and have no official connections, all groups share a common interest in familial and population based cancer. For example, kConFab recruits families at high genetic risk of breast, ovarian and prostate cancer through Family Cancer Clinics located in every State and Territory of Australia and return our research generated germ-line mutation test results back to family members and the relevant treating FCC. In one sense kConFab is the research arm of the national Family Cancer Clinics. Many of the consortia members are health professionals (medical oncologists, surgeons, genetic counsellors, cancer specialists, research scientists) working in the Family Cancer Clinics and major research institutions through-out Australia and New Zealand.

A joint annual meeting has particular value for the groups mentioned as it provides a forum to develop and discuss new research findings, clinical trials and implementation of technologies about families with multiple cases of breast, ovarian, prostate, melanoma, sarcoma, leukaemia and colorectal cancers. 

Due to COVID-19 restrictions in NSW the conference has been changed to a 100% virtual event.

The meeting will still run for four days with the FCC meeting on Tuesday 31st August followed by the clinical/scientific/psychosocial running over the Wed. - Fri.

If you have paid for in-person attendance, your registration has been changed to a virtual one and you will be refunded the difference after the conference.

The program shall be released very soon, there is some fantastic work to be presented this year albeit in a virtual format.

Virtual Registration is open- we look forward to e-seeing you there!

FAC 2021 will be delivered in a hybrid format, combining an in-person conference experience with an online component.

What is a hybrid conference?

A hybrid conference allows delegates to attend either in person at the event or online from wherever they are in the world.

In-Person attendees will experience all the usual highlights of the FAC meeting, including leading keynote presentations, opportunity to submit abstracts to present an oral or poster presentation, opportunity to attend breakout sessions, networking opportunities and an industry exhibition.

Virtual attendees will be able to view the live-streamed presentations in the plenary sessions and participate in the Q & A.

We are aiming for a hybrid event - in-person with a virtual component however our back up plan in the event the conference is impacted by COVID-19 will be a fully virtual conference.  Please read our Refund Policy to find out what happens in the event of COVID-19 impacting the conference HERE.  

• Genetics of breast, ovarian, prostate, colorectal cancer, melanoma and sarcoma

• Risk management of a BRCA or p53 mutation carrier

• New targeted clinical trials – the PARPi pathway & cancer prevention trials

• Clinical work in ER PR and HER2 negative breast cancer

• Genes involved in neoplastic development

• Utilization of new technologies in molecular pathology for early diagnosis

• New bio markers for breast, ovarian, prostate, sarcoma, melanoma & colorectal cancer

Professor Doug Easton, Cambridge University, UK

Professor James Flanagan, Imperial College, London

Professor David Huntsman, Vancouver General Hospital, BC Cancer Agency and UBC, Canada

Professor Joanne Morris, University of Birmingham, UK

Professor Marjanka Schmidt, Netherlands Cancer Institute, Amsterdam

Professor Clare Turnbull, Institute of Cancer Research, London, UK

Mandy Ballanger, Garvan Institute of Medical Research, Sydney

James Flanagan, Imperial College London

Laura Forrest, The Peter MacCallum Cancer Centre, Melbourne

John Hopper, The University of Melbourne, Melbourne

Finlay Macrae, The Royal Melbourne Hospital, Melbourne

Melissa Southey, Monash University, Melbourne

Lucinda Salmon, The Austin Hospital, Melbourne

Heather Thorne, The Peter MacCallum Cancer Centre, Melbourne

Rachel Williams, Prince of Wales Hospital, Sydney